LGND vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LGND presents a dichotomy between exceptional operational profitability and poor deterministic health/value scores. While the company boasts a massive 46.42% profit margin and strong revenue growth (39.4%), the Piotroski F-Score of 3/9 indicates weak financial trend momentum. The stock is trading at a significant premium to its Graham Number ($84.23) and Intrinsic Value ($42.91), suggesting the market is pricing in aggressive future growth. Bearish insider activity and a weak technical trend further temper the outlook despite strong analyst target prices.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
LGND vs MRK: Head-to-Head Comparison
This page compares Ligand Pharmaceuticals Incorporated (LGND) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.